Physician profile
John P Levins
NPI 1881665974
$3,095.37
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,230 · 2020: $150 · 2021: $681 · 2022: $1,034.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $754.49 | 2019-2022 | |
| Glaxosmithkline, LLC. | $412.04 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $262.12 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $253.24 | 2019 | |
| Lilly USA, LLC | $204.91 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $177.41 | 2021-2022 | |
| Mylan Specialty L.P. | $153.06 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $127.53 | 2019-2022 | |
| Amarin Pharma, INC. | $91.81 | 2019-2022 | |
| Abbvie INC. | $88.04 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.87 | 2019-2022 | |
| Dexcom, INC. | $79.01 | 2019-2022 | |
| Pfizer INC. | $69.96 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $66.35 | 2019 | |
| Mannkind Corporation | $44.35 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.55 | 2021-2022 | |
| Horizon Therapeutics Plc | $26.61 | 2019 | |
| Philips North America LLC | $23.90 | 2020 | |
| Novartis Pharmaceuticals Corporation | $22.12 | 2021 | |
| Hikma Pharmaceuticals USA | $20.24 | 2022 | |
| Merck Sharp & Dohme LLC | $19.14 | 2019 | |
| Genentech USA, INC. | $17.86 | 2020 | |
| Boston Scientific Corporation | $17.34 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.29 | 2020 | |
| Nevro Corp. | $13.65 | 2022 | |
| Depuy Synthes Sales INC. | $12.25 | 2019 | |
| Amgen INC. | $11.23 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Levins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.